A Phase II Study of Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma and Melanomas That Arise on Chronically Sun Damaged Skin.
Phase of Trial: Phase II
Latest Information Update: 12 Dec 2016
At a glance
- Drugs Imatinib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms BUS255
- 31 Aug 2018 Biomarkers information updated
- 16 Oct 2016 Status changed from active, no longer recruiting to completed.
- 19 Jan 2016 Planned End Date changed from 1 Oct 2014 to 1 Aug 2016 as per ClinicalTrials.gov record.